ClinicalTrials.gg
CompletedNCT05012579Updated Feb 13, 2024Results posted

Transcutaneous Afferent Patterned Stimulation (TAPS) for Reduction of Parkinson's Disease (PD) Related Action Tremor

An interventional study of Cala Device in Parkinson Disease, sponsored by Cala Health, Inc.. Completed at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by Cala Health, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Nov 2020, registered Aug 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Enrollment
554th of 1,257
40 · median 36
Started
2020
with 89 others
No phase
586 of 1,650
147 open now
Registered
1,192nd of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 554th largest by enrollment of the 1,257 interventional ones that give a count, is one of 90 that started in 2020, is one of 586 with no phase, and was the 1,192nd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

300 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

Demonstrate safety and efficacy of TAPS delivered by a Cala device as a treatment for action tremor in subjects with Parkinson's disease hand tremor

Read the detailed description

40 patients with PD with at least mild postural tremor were enrolled in a four-week, prospective, single-arm, open-label study of twice daily TAPS therapy. Due to the COVID-19 pandemic, TAPS devices were shipped to patients to run the study remotely. Unsupervised motion assessments were captured at home, and at the beginning and end of the four weeks by telemedicine.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be ≥22 years of age
  • Competent and willing to provide written, to participate in the study
  • postural tremor as defined by:

    • Dominant hand/arm exhibiting postural tremor ≥ 2 (while in the off state) as assessed by the MDS-UPDRS postural tremor score
  • Stable dose of Parkinson's disease medications, if applicable, for 30 days prior to study entry
  • Willing to comply with study protocol requirements including:

    • Having the ability to do telemedicine or video calls for study visits
    • remaining on a stable dosage of Parkinson's medications, if applicable, during the duration of the study
    • no significant caffeine consumption within 8 hours of study visits

Exclusion criteria

Exclusion Criteria:

  • Implanted electrical medical device, such as a pacemaker, defibrillator, or deep brain stimulator
  • Suspected or diagnosed epilepsy or other seizure disorder
  • Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site
  • Peripheral neuropathy affecting the tested upper extremity
  • Presence of any other neurodegenerative disease or dementia. These may include: multisystem atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and Alzheimer's disease.
  • Botulinum toxin injection for hand tremor within 6 months prior to study enrollment
  • Are participating or have participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by the Sponsor
  • Significant caffeine consumption within 8 hours of study enrollment, which may confound the results of the study, where significant caffeine is considered more than 95 mg (equivalent to a cup of coffee).
  • Subjects unable to communicate with the investigator and staff
  • Any health condition that in the investigator's opinion should preclude participation in this study
  • Pregnancy or anticipated pregnancy during the course of the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    TAPS delivered by Cala device

    Two 40-minute TAPS sessions daily for 28 days, recommended as once in the morning and once in the evening.

    Device: Cala Device

Interventions

  • DeviceCala Device

    transcutaneous afferent patterned stimulation (TAPS)

06

What researchers measure

Primary outcomes

  1. Tremor Power

    Pre-specified effectiveness endpoints included improvements in (1) objective postural tremor power (primary outcome; assessed using an accelerometer on the device under standard of care medication state at home).

    Time frame: 4 weeks

Secondary outcomes

  1. Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    Improvement of clinician-ratings of Movement Disorder Society Unified PD Rating Scale (MDS-UPDRS) Part III \[Goetz, C.G. et al. Wiley Intersci. 2008\] (co-secondary; in medication-off state). Clinician rated patients' tremor pre and post therapy on a scale of 0-4. 0=Normal (no tremor), 4=Severe.

    Time frame: 4 weeks

  2. Bain and Findley Activities of Daily Living (BF-ADL)

    Improvement of patient-ratings of the Bain and Findley Activities of Daily Living (BF-ADL) \[Bain PG, et al. Journal of Neurol, Neuros \& Psych 1993\] (co-secondary; in medication-off state). Patients' rated ability to perform specific activities pre and post therapy on a scale from 1-4. 1=Able to do the activity without difficulty, 4=Cannot do the activity by yourself.

    Time frame: 4 weeks

  3. Percentage of Patients With Clinician and Patient Global Impressions of Improvement Rated < 4 (CGI-I, PGI-I)

    Clinician and Patient global impressions of improvement (CGI-I, PGI-I; exploratory) post therapy. This is a rated scale from 1-7, with 1=Very Much Improved to 7=Very Much Worse. Percentage of patients with ratings \< 4 (including very much improved, much improved and improved) were computed respectively for CGI-I and PGI-I.

    Time frame: 4 weeks

07

Results

Posted Feb 13, 2024

Participant flow

Participant flow — Overall Study
MilestoneTAPS Delivered by Cala Device
Started40
Completed37
Not completed3

Outcome measures

PrimaryTremor Power

Pre-specified effectiveness endpoints included improvements in (1) objective postural tremor power (primary outcome; assessed using an accelerometer on the device under standard of care medication state at home).

Time frame:
4 weeks
Reported as:
Median · Percentage of tremor power reduction
Tremor Power
Percentage of tremor power reductionSingle Arm - TAPS Delivered by Cala Device
Tremor Power64 (54 to 79)
SecondaryMovement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

Improvement of clinician-ratings of Movement Disorder Society Unified PD Rating Scale (MDS-UPDRS) Part III \[Goetz, C.G. et al. Wiley Intersci. 2008\] (co-secondary; in medication-off state). Clinician rated patients' tremor pre and post therapy on a scale of 0-4. 0=Normal (no tremor), 4=Severe.

Time frame:
4 weeks
Reported as:
Mean · units on a scale
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
units on a scaleSingle Arm - TAPS Delivered by Cala Device
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)0.6 ± 0.5
SecondaryBain and Findley Activities of Daily Living (BF-ADL)

Improvement of patient-ratings of the Bain and Findley Activities of Daily Living (BF-ADL) \[Bain PG, et al. Journal of Neurol, Neuros \& Psych 1993\] (co-secondary; in medication-off state). Patients' rated ability to perform specific activities pre and post therapy on a scale from 1-4. 1=Able to do the activity without difficulty, 4=Cannot do the activity by yourself.

Time frame:
4 weeks
Reported as:
Mean · units on a scale
Bain and Findley Activities of Daily Living (BF-ADL)
units on a scaleSingle Arm - TAPS Delivered by Cala Device
Bain and Findley Activities of Daily Living (BF-ADL)0.5 ± 0.5
SecondaryPercentage of Patients With Clinician and Patient Global Impressions of Improvement Rated < 4 (CGI-I, PGI-I)

Clinician and Patient global impressions of improvement (CGI-I, PGI-I; exploratory) post therapy. This is a rated scale from 1-7, with 1=Very Much Improved to 7=Very Much Worse. Percentage of patients with ratings \< 4 (including very much improved, much improved and improved) were computed respectively for CGI-I and PGI-I.

Time frame:
4 weeks
Reported as:
Number · percentage of patients with improvement
Percentage of Patients With Clinician and Patient Global Impressions of Improvement Rated < 4 (CGI-I, PGI-I)
percentage of patients with improvementSingle Arm - TAPS Delivered by Cala Device
PGI-I80
CGI-I77

Adverse events

Collected over 4 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAPS Delivered by Cala Device0/40 (0%)0/40 (0%)8/40 (20%)
Most frequent other events
Most frequent other events
EventTAPS Delivered by Cala Device
sore/lesionSkin and subcutaneous tissue disorders2/40
Unsteady gaitGeneral disorders1/40
significant and persistent skin irritationSkin and subcutaneous tissue disorders1/40
persistent pain from stimulationMusculoskeletal and connective tissue disorders1/40
significant discomfort with stimulationGeneral disorders1/40
twitching of ring fingerMusculoskeletal and connective tissue disorders1/40
anxiety/insomnia/worsening of tremor at nightGeneral disorders1/40

Baseline characteristics

40 enrolled subjects with PD

Age, Continuous
Age, Continuous(years)TAPS Delivered by Cala Device
Mean67.1 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)TAPS Delivered by Cala Device
Female10
Male30
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TAPS Delivered by Cala Device
Race — Asian6
Race — African American1
Race — Caucasian33
08

Study locations

1 site
  • Cala Clinic
    Burlingame, California 94010, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Mar 2021, 4 months.

Results were first posted in Feb 2024, 2 years 11 months after primary completion.

Of 76 industry-sponsored interventional studies with no phase under Parkinson Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 4 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2021
First posted
Aug 19, 2021
StartActual
Nov 11, 2020
Primary completionActual
Mar 12, 2021
CompletionActual
Mar 12, 2021
Results first posted
Feb 13, 2024
Last update
Feb 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05012579
Lead sponsor
Cala Health, Inc.
Responsible party
Sponsor
First posted
Aug 19, 2021
Start date
Nov 11, 2020
Primary completion
Mar 12, 2021
Completion
Mar 12, 2021
Results posted
Feb 13, 2024
Last update
Feb 13, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion